Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

QuantiFERON Access Clinical Performance Study Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04243031
Recruitment Status : Withdrawn (Business Decision)
First Posted : January 27, 2020
Last Update Posted : September 16, 2020
Sponsor:
Information provided by (Responsible Party):
QIAGEN Gaithersburg, Inc

Brief Summary:
Approximately 225 samples, obtained from participants with varying risk factors for TB infection and disease, will be tested using the QFT Access Kit and the comparator device QFT-Plus.

Condition or disease Intervention/treatment
Tuberculosis (TB) Device: QFT Access

Layout table for study information
Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Non-interventional, Prospective Clinical Performance Study of the QuantiFERON Access Kit to Demonstrate Clinical Accuracy Compared to a CE-marked In-Vitro Diagnostic Medical Device, in Participants With Varying Risk Factors for TB Infection and Disease.
Estimated Study Start Date : April 1, 2020
Estimated Primary Completion Date : August 1, 2020
Estimated Study Completion Date : November 1, 2020

Group/Cohort Intervention/treatment
All subjects
Those with TB and those without TB.
Device: QFT Access
Measure of Interferon Gamma




Primary Outcome Measures :
  1. TB Result [ Time Frame: At time of enrollment ]
    QFT Access result compared to the QFT-Plus result (positive, negative)


Biospecimen Retention:   Samples With DNA
Plasma, whole blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Participants coming to clinic
Criteria

Inclusion Criteria:

  • 1. Be ≥ 18 years of age,
  • 2. Have received no TB treatment or received treatment for less than 14 consecutive days.
  • 3. Provide Informed Consent.

Exclusion Criteria:

  • 1. They do not meet the inclusion criteria,
  • 2. Blood handling was not completed using QFT-Plus
  • 3. Incubation was <16 and >24 hours
  • 4. Improperly collected and/or stored samples per Instructions For Use
Layout table for additonal information
Responsible Party: QIAGEN Gaithersburg, Inc
ClinicalTrials.gov Identifier: NCT04243031    
Other Study ID Numbers: TMF-17-1056-1
First Posted: January 27, 2020    Key Record Dates
Last Update Posted: September 16, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections